These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15735458)

  • 1. Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.
    Zala C; Alexander CS; Ochoa C; Guillemi S; Ting LS; Bonner S; Cahn P; Harrigan PR; Montaner JS
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):363-4. PubMed ID: 15735458
    [No Abstract]   [Full Text] [Related]  

  • 2. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
    Mole L; Schmidgall D; Holodniy M
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):260-5. PubMed ID: 11464145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
    Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
    HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 6. Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
    Boyd MA; Burger DM; Phanuphak P; Cooper DA
    AIDS; 2006 Apr; 20(7):1083-5. PubMed ID: 16603870
    [No Abstract]   [Full Text] [Related]  

  • 7. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
    Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for ritonavir intolerance and outcome after change to indinavir.
    Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
    AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of indinavir and ritonavir on warfarin anticoagulant activity.
    Gatti G; Alessandrini A; Camera M; Di Biagio A; Bassetti M; Rizzo F
    AIDS; 1998 May; 12(7):825-6. PubMed ID: 9619821
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
    Floridia M; Tomino C; Bucciardini R; Ricciardulli D; Fragola V; Pirillo MF; Amici R; Giannini G; Galluzzo CM; Andreotti M; Seeber AC; Ammassari A; Cingolani A; Lazzarin A; Scalise G; Cargnel A; Suter F; Milazzo F; Pastore G; Moroni M; Ciammarughi R; Pini R; Carosi G; D'Amato C; Contu L; Concia E; Bonazzi L; Aiuti F; Vigevani G; Vella S;
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1809-20. PubMed ID: 11118067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.
    Haas DW; Johnson B; Nicotera J; Bailey VL; Harris VL; Bowles FB; Raffanti S; Schranz J; Finn TS; Saah AJ; Stone J
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2131-7. PubMed ID: 12821458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crixivan, Norvir combination therapy studied.
    Strain W
    Posit Living; 1999 Apr; 8(3):16. PubMed ID: 12492057
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
    [No Abstract]   [Full Text] [Related]  

  • 14. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 16. Protease inhibitors in antiviral therapy of paediatric HIV disease.
    Manfredi R; Monari P; Donzelli C; Furlini G; Re MC; Chiodo F
    Acta Paediatr; 1998 Jul; 87(7):814-6. PubMed ID: 9722261
    [No Abstract]   [Full Text] [Related]  

  • 17. Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.
    Solas C; Petit N; Orticoni M; Durand A; Gastaut JA; Lacarelle B
    Pathol Biol (Paris); 2002 Nov; 50(9):565-7. PubMed ID: 12490421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
    Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
    Casado JL; Moreno A; Sabido R; Martí-Belda P; Antela A; Dronda F; Perez-Elías MJ; Moreno S
    HIV Clin Trials; 2000; 1(1):13-9. PubMed ID: 11590485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.